A simple blood test that could dramatically improve how doctors predict and prevent heart disease is gaining serious attention from cardiologists. While most people still rely on the traditional cholesterol
check during routine health screenings, new research suggests it may be time for a more precise alternative.
Scientists at Northwestern Medicine in the United States have found that measuring a protein called apolipoprotein B (apoB) may offer a far superior way of assessing heart attack and stroke risk compared to standard LDL or non-HDL cholesterol tests.
How Cholesterol Helps Track Heart Risk?
For decades, cholesterol testing has been the gold standard for evaluating cardiovascular risk. High levels of LDL, often labelled “bad cholesterol”, have long been associated with a greater chance of heart disease. However, this new research highlights a critical limitation: two people with identical cholesterol readings can carry very different levels of actual risk.
The reason lies in the number of harmful particles circulating in the blood. Traditional tests measure the amount of cholesterol, but not how many dangerous lipoprotein particles are actually transporting it. These particles can lodge in artery walls, leading to dangerous blockages over time.
What is apoB?
ApoB is a blood work test, which measures the number of these atherogenic (plaque-forming) particles. Each harmful particle carries exactly one apoB protein, making it a much more accurate marker of true cardiovascular risk.
“Research strongly shows that apolipoprotein B (apoB) is better at identifying who is at risk, because it counts the total number of harmful particles in the blood,” explained lead researcher Ciaran Kohli-Lynch of Northwestern University Feinberg School of Medicine.
In one of the largest simulations of its kind, researchers analysed data from over 250,000 adults who required cholesterol-lowering treatment but had not yet developed heart disease. Using advanced computer modelling, they compared three approaches: treatment guided by LDL cholesterol, non-HDL cholesterol, and apoB levels.
The results were striking. The apoB-guided strategy prevented significantly more heart attacks and strokes than the current standard methods. Importantly, the improved outcomes came at a cost that represented good value for healthcare systems.
This new approach could be particularly valuable because heart disease remains one of the leading causes of death worldwide. Better risk assessment means doctors can identify high-risk patients earlier and tailor treatment more effectively — potentially saving thousands of lives each year.
Despite the promising findings, apoB testing is not yet routine in most clinics. It usually needs to be specifically requested, and many doctors continue to rely on the familiar LDL measurements they have used for years.
What This Means for Patients?
If you have a family history of heart disease, or if your doctor has flagged raised cholesterol in the past, it may be worth discussing apoB testing at your next check-up. While not yet universally recommended, awareness is growing rapidly among specialists.
The study, published in the Journal of the American Medical Association (JAMA), adds to a growing body of evidence that apoB could become the new gold standard in preventive cardiology.
As heart disease prevention moves into a more personalised era, this straightforward blood test could represent one of the most important shifts in cardiovascular care in recent decades — offering sharper insights and, ultimately, better protection for millions of people.
